[go: up one dir, main page]

WO2006115633A3 - Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer - Google Patents

Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer Download PDF

Info

Publication number
WO2006115633A3
WO2006115633A3 PCT/US2006/010170 US2006010170W WO2006115633A3 WO 2006115633 A3 WO2006115633 A3 WO 2006115633A3 US 2006010170 W US2006010170 W US 2006010170W WO 2006115633 A3 WO2006115633 A3 WO 2006115633A3
Authority
WO
WIPO (PCT)
Prior art keywords
intra
chlorotoxin conjugate
operative
cyanine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/010170
Other languages
French (fr)
Other versions
WO2006115633A2 (en
Inventor
Miqin Zhang
James Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Fred Hutchinson Cancer Center
Original Assignee
University of Washington
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Fred Hutchinson Cancer Center filed Critical University of Washington
Priority to AT06739100T priority Critical patent/ATE502048T1/en
Priority to EP06739100A priority patent/EP1877428B1/en
Priority to DE602006020710T priority patent/DE602006020710D1/en
Publication of WO2006115633A2 publication Critical patent/WO2006115633A2/en
Publication of WO2006115633A3 publication Critical patent/WO2006115633A3/en
Priority to US11/897,721 priority patent/US8778310B2/en
Anticipated expiration legal-status Critical
Priority to US14/273,374 priority patent/US20140241993A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)

Abstract

A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.
PCT/US2006/010170 2005-04-22 2006-03-20 Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer Ceased WO2006115633A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT06739100T ATE502048T1 (en) 2005-04-22 2006-03-20 FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRAOPERATIVE VISIBILITY OF CANCER
EP06739100A EP1877428B1 (en) 2005-04-22 2006-03-20 Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
DE602006020710T DE602006020710D1 (en) 2005-04-22 2006-03-20 FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER
US11/897,721 US8778310B2 (en) 2005-04-22 2007-08-31 Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer
US14/273,374 US20140241993A1 (en) 2005-04-22 2014-05-08 Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67428005P 2005-04-22 2005-04-22
US60/674,280 2005-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/897,721 Continuation US8778310B2 (en) 2005-04-22 2007-08-31 Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer

Publications (2)

Publication Number Publication Date
WO2006115633A2 WO2006115633A2 (en) 2006-11-02
WO2006115633A3 true WO2006115633A3 (en) 2006-12-28

Family

ID=36609637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010170 Ceased WO2006115633A2 (en) 2005-04-22 2006-03-20 Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer

Country Status (6)

Country Link
US (3) US20070154965A1 (en)
EP (1) EP1877428B1 (en)
AT (1) ATE502048T1 (en)
DE (1) DE602006020710D1 (en)
ES (1) ES2360519T3 (en)
WO (1) WO2006115633A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
ATE502048T1 (en) 2005-04-22 2011-04-15 Univ Washington FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRAOPERATIVE VISIBILITY OF CANCER
ES2390314T3 (en) 2006-02-24 2012-11-08 Medibeacon Development, Llc Optical agents for use in surgery
WO2007122259A1 (en) * 2006-04-25 2007-11-01 Centre National De La Recherche Scientifique (Cnrs) Functionalization of gold nanoparticles with oriented proteins. application to the high-density labelling of cell membranes
CN101848734B (en) 2007-05-16 2013-08-28 通用电气医疗集团股份有限公司 Labeled IIGF-binding peptides for imaging
US8541006B2 (en) * 2007-07-30 2013-09-24 University Of Maryland, Baltimore Methods and devices for the detection of biofilm
WO2009021136A1 (en) * 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
WO2009049184A2 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
US7892760B2 (en) * 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
WO2009126835A2 (en) * 2008-04-09 2009-10-15 University Of Washington Techtransfer Invention Licensing Magnetic nanoparticle and method for imaging t cells
JP5497006B2 (en) * 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション Plectin-1 targeting agent for detection and treatment of ductal adenocarcinoma
EP2300045A1 (en) 2008-05-15 2011-03-30 Transmolecular, Inc. Treatment of metastatic tumors
WO2010028013A2 (en) * 2008-09-02 2010-03-11 University Of Maryland, Baltimore In vivo biofilm infection diagnosis and treatment
EP3238735A1 (en) 2010-02-04 2017-11-01 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CA2799169C (en) * 2010-05-11 2019-07-23 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2013003507A1 (en) * 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
BR112016005802A2 (en) 2013-09-17 2017-09-12 Blaze Bioscience Inc chlorotoxin conjugates and methods of use
EP3442996A4 (en) 2016-04-12 2019-11-27 Blaze Bioscience, Inc. METHODS OF TREATMENT INVOLVING CHLOROTOXIN CONJUGATES
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
WO2000062807A1 (en) * 1999-04-21 2000-10-26 The Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407582A1 (en) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen CIRCUIT ARRANGEMENT FOR A CONTROL LOOP
US6130101A (en) * 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
CN1379687A (en) * 1999-09-14 2002-11-13 生物医学阿佩则系统有限公司 Magnetic nanoparticles having biochemial activity, method for production thereof and their use
WO2001037721A2 (en) * 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10020376A1 (en) * 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamic markers
US20030021810A1 (en) 2001-06-26 2003-01-30 Sontheimer Harald W. Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
US6972326B2 (en) * 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
EP2182004A1 (en) 2002-05-31 2010-05-05 Transmolecular, Inc. Combination therapy of isotopically labelled chlorotoxin with temozolomide
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
DE10328251A1 (en) 2003-06-24 2005-01-13 Toximed Gmbh Pharmaceutical agent
WO2005053611A2 (en) 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
DE602005019728D1 (en) 2004-04-06 2010-04-15 Transmolecular Inc DIAGNOSIS AND TREATMENT OF MYELOID AND LYMPHOID CELL CANCER WITH CHLOROTOXINE OR DERIVATIVE
GB0422901D0 (en) 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) * 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
ATE502048T1 (en) 2005-04-22 2011-04-15 Univ Washington FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRAOPERATIVE VISIBILITY OF CANCER
CN103103238B (en) 2005-08-18 2016-08-10 Ambrx公司 A kind of manufacture in cell has selected amino acid whose antibody or the method for antibody fragment polypeptide in specific location
EP2013233A2 (en) 2006-03-31 2009-01-14 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
WO2007137163A2 (en) 2006-05-19 2007-11-29 Georgia Tech Research Corporation Abc transporter ligand
CN101003788A (en) 2006-09-21 2007-07-25 武汉大学 Anti tumor translocation peptide of scorpion, preparation method and application
CN100564517C (en) 2006-09-21 2009-12-02 武汉大学 A kind of anti-glioma peptide of scorpion and its production and application
AR063384A1 (en) 2006-10-25 2009-01-28 Amgen Inc THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2009021136A1 (en) 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
WO2009049184A2 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
AU2008352925A1 (en) 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition of angiogenesis
CN101270158B (en) 2008-04-30 2010-12-22 武汉大学 Target glioma resistant protein, preparation method and application
EP2300045A1 (en) 2008-05-15 2011-03-30 Transmolecular, Inc. Treatment of metastatic tumors
JP5711118B2 (en) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン HNGAL and affinity protein muteins with affinity for a given target
US20100098637A1 (en) 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (en) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 Genetic engineering tumor targeting KCT-W1 polypeptides and preparation method and application
CN106519588B (en) 2009-11-09 2019-08-20 华盛顿大学商业化中心 Functionalized chromophoric polymer dots and their bioconjugates
CN101921769B (en) 2010-01-11 2012-07-25 山西大学 Recombinant adenovirus, preparation method and application thereof
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
EP3238735A1 (en) 2010-02-04 2017-11-01 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
CN101824084A (en) 2010-04-08 2010-09-08 山西大学 Targeting antiglioma protein and application thereof
CA2799169C (en) 2010-05-11 2019-07-23 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
DK2606061T3 (en) 2010-08-16 2017-11-06 Pieris Pharmaceuticals Gmbh HEPCIDIN BINDING PROTEINS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
WO2000062807A1 (en) * 1999-04-21 2000-10-26 The Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERLIER JUDITH E; ROTHE ANCA; BULLER GAYLE ET AL: "Quantitative comparison of long-wavelength Alexa Fluor dyes to Cy dyes: fluorescence of the dyes and their bioconjugates", THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 51, December 2003 (2003-12-01), pages 1699 - 1712, XP002398136 *
CITRIN D ET AL: "In vivo tumor imaging in mice with near-infrared labeled endostatin", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 3, no. 4, 2004, pages 481 - 488, XP002326516, ISSN: 1535-7163 *
DESHANE JESSY; GARNER CRAIG C; SONTHEIMER HARALD: "Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 6, 7 February 2003 (2003-02-07), pages 4135 - 4144, XP002398052 *
SOROCEANU L ET AL: "USE OF CHLOROTOXIN FOR TARGETING OF PRIMARY BRAIN TUMORS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 21, 1 November 1998 (1998-11-01), pages 4871 - 4879, XP001146137, ISSN: 0008-5472 *
VEISEH O, SUN C, GUNN J ET AL.: "Optical and MRI multifunctional nanoprobe for targeting gliomas", NANO LETTERS, vol. 5, no. 6, June 2005 (2005-06-01), pages 1003 - 1008, XP002398053 *
WEISSLEDER R ET AL: "SHEDDING LIGHT ONTO LIVE MOLECULAR TARGETS", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 9, no. 1, January 2003 (2003-01-01), pages 123 - 128, XP008058423, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
WO2006115633A2 (en) 2006-11-02
EP1877428A2 (en) 2008-01-16
US20080279780A1 (en) 2008-11-13
ES2360519T3 (en) 2011-06-06
DE602006020710D1 (en) 2011-04-28
US20140241993A1 (en) 2014-08-28
EP1877428B1 (en) 2011-03-16
ATE502048T1 (en) 2011-04-15
US8778310B2 (en) 2014-07-15
US20070154965A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
WO2006115633A3 (en) Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer
WO2008022043A3 (en) Intraoperative imaging of renal cortical tumors and cysts
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008076467A3 (en) Intraoperative imaging methods
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008046911A3 (en) Novel human micrornas associated with cancer
WO2007009755A3 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2007118214A3 (en) Antibody compositions and methods for treatment of neoplastic disease
WO2008094545A3 (en) Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2006102272A8 (en) Methods for treating tumors and cancerous tissues
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2006011810A3 (en) Mr imaging method for the discrimination between healthy and tumour tissue
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2007013950A3 (en) Combination therapy of her expressing tumors
WO2008001101A3 (en) Pharmaceutical combinations
WO2010008519A3 (en) In vitro diagnostic markers comprising carbon nanoparticles and kits
IL185501A0 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008031038A3 (en) Pre- and intra-operative localization of penile sentinel nodes
WO2008043101A3 (en) Intraoperative imaging of hepatobiliary structures
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
WO2006035300A3 (en) A process for the preparation of meropenem

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006739100

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU